• Follow Us On : 

Appier Recognized as an IDC Innovator for Asia-Pacific Data-as-a-Service Provider 2018


Redaksi | Selasa,27 Maret 2018 - 14:11:36 WIB
Dibaca: 305 kali 
Appier Recognized as an IDC Innovator for Asia-Pacific Data-as-a-Service Provider 2018

SINGAPOREMedia OutReach - March 27, 2018 - Appier, a leading artificial intelligence (AI) company, has been named by International Data Corporation (IDC) as an IDC Innovator in the Asia-Pacific Data-as-a-Service Provider (DaaS) category for 2018.

Appier earned this recognition for its CrossX advertising platform which uses AI to identify and deliver the ideal audience for an organization's campaign.

The platform draws on the extensive knowledge of user behavior and device ownership that CrossX AI has compiled to decide what audiences to target, at what time of day, and on what screen.

BACA : Appier's Aixon Connects to Google Advertising Platforms

"One of the biggest pain points for organizations is in delivering better customer experience and obtaining a good single customer view. Appier delivers a platform solution that combines audience targeting, inventory and bidding optimization that takes the guesswork out of cross-screen campaigns," said Chwee Kan Chua, IDC's Global Research Director for Big Data & Analytics and Cognitive/Artificial Intelligence in the Asia/Pacific region.

"Appier is honored to be recognized by IDC as an innovator in DaaS. We were the first company to bring an AI-as-a-Service model to our customers in Asia Pacific and this has enabled them to ease the implementation of AI in their organizations. Appier will continue to build more AI-driven solutions to help our enterprise organizations," said Chih-Han Yu, co-founder and CEO, Appier.

The complete report, IDC Innovators: Asia/Pacific Data-as-a-Service Provider, 2018, February 2018, IDC #AP43564318, is available to IDC subscribers at www.idc.com.

BACA : Appier Demonstrates Breakthrough in Creativity in Artificial Intelligence


Akses Wahanariau.com Via Mobile m.Wahanariau.com
Untuk Berbagi Berita / Informasi / Peristiwa
Silahkan SMS ke nomor HP : 085271472010
atau email ke alamat : [email protected]
Harap camtumkan detail data diri Anda
Pengutipan Berita dan Foto, Cantumkan Wahanariau.com Sebagai Sumber Tanpa Penyingkatan
TULIS KOMENTAR
BERITA TERKAIT
Kamis,19 Januari 2017 - 23:23:43 WIB

Appier Named in CB Insights’ Second Annual AI 100 Companies

SINGAPORE - Media OutReach - December 19, 2017 - Appier, a leading artificial intelligence (AI) comp

Jumat,08 Juni 2018 - 20:13:05 WIB

Appier Wins Most Promising AI Solution Category of the NWA Information Management Awards 2018

Award established Appier as Asia's leader in AI in APAC SINGAPORE - Media OutReach -

Selasa,10 April 2018 - 14:47:58 WIB

Appier Brings AI-driven Insights To LINE With Aixon Integration

Integration will also enable real-time, cross-platform marketing for LINE Business Connect enterpris

Selasa,07 Agustus 2018 - 13:15:17 WIB

Appier Launches AI-driven Proactive Marketing Automation Platform AIQUA

TAIWAN - August 7, 2018 - Appier, a leading artificial intelligence (AI) company, today an

Kamis,26 Juli 2018 - 14:17:05 WIB

Appier Strengthens AI Team with New Chief Artificial Intelligence Scientist

TAIWAN - Media OutReach - July 26 2018 - Appier, a leading artificial intelligen

Kamis,15 Februari 2018 - 16:51:53 WIB

Appier Demonstrates Breakthrough in Creativity in Artificial Intelligence

Pioneering study takes a unique approach to applying cutting edge deep learning technology to appare

BERITA LAINNYA
Rabu,15 Agustus 2018 - 00:28:28 WIB

More than 400 IT Professionals Joined CLOUDSEC Hong Kong 2018

CHINA - 14 August 2018 - More than 400 professionals from Hong Kong and Macau today joined CLOUDSEC

Rabu,15 Agustus 2018 - 00:22:40 WIB

Avnet Memperluas Jaringan dengan Microchip

Dinobatkan sebagai Mitra Pemasaran Global bagi Microsemi Portfolio   PHOENIX - 14 AGUSTUS 201

Selasa,14 Agustus 2018 - 00:01:23 WIB

Sihuan Pharmaceutical’s Self-Developed Innovative Oncology Drug Pirotinib Commenced Phase II Clinical Trial in China

Led by Top Oncologist Professor Wu Yilong Expected to Commence Phase III Clinical Trial in 2H2019. D

BERGABUNG DI SINI
KABAR POPULER
IKUTI BERITA KAMI